Skip Navigation

Cardiovascular Research 2006 71(1):6-7; doi:10.1016/j.cardiores.2006.05.007
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Neumann, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neumann, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2006, European Society of Cardiology

The cardiac β-adrenoceptors: Where and why?

Joachim Neumann*

Institut für Pharmakologie und Toxikologie, Medizinische Fakultät, Martin-Luther Universität Halle-Wittenberg, Magdeburger Str. 4, 06112 Halle, Germany

* Tel.: +49 345 557 1686; fax: +49 345 557 18 35. Email address: joachim.neumann@medizin.uni-halle.de

Received 2 May 2006; accepted 5 May 2006

The first 10% of the full text of this article appears below.

See article by Boivin et al. [1] (pages 69–78) in this issue.

The family of G-protein-coupled heptahelical receptors are widely distributed in the human body. Of special clinical importance are β-adrenoceptors, which mediate the effects of the sympathetic nervous system. In the heart, they induce, at least to a large extent, the inotropic effects of catecholamines. They confer signals from their ligands to the cell, and this signal transduction process classically runs via G-proteins to downstream effectors. . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?